Today colorectal cancer(CRC)is one of the leading causes of cancer death worldwide.This disease is poorly chemo-sensitive toward the existing medical treatments so that new and more effective therapeutic agents are ur...Today colorectal cancer(CRC)is one of the leading causes of cancer death worldwide.This disease is poorly chemo-sensitive toward the existing medical treatments so that new and more effective therapeutic agents are urgently needed and intensely sought.Platinum drugs,oxaliplatin in particular,were reported to produce some significant benefit in CRC treatment,triggering the general interest of medicinal chemists and oncologists for metal-based compounds as candidate anti-CRC drugs.Within this frame,gold compounds and,specifically,the established antiarthritic drug auranofin with its analogs,form a novel group of promising anticancer agents.Owing to its innovative mechanism of action and its favorable pharmacological profile,auranofin together with its derivatives are proposed here as novel experimental agents for CRC treatment,capable of overcoming resistance to platinum drugs.Some encouraging results in this direction have already been obtained.A few recent studies demonstrate that the action of auranofin may be further potentiated through the preparation of suitable pharmaceutical formulations capable of protecting the gold pharmacophore from unselective reactivity or through the design of highly synergic drug combinations.The perspectives of the research in this field are outlined.展开更多
基金funding the project“Advanced mass spectrometry tools for cancer research:novel applications in proteomics,metabolomics and nanomedicine”(Multi-user Equipment Program 2016,Ref.code 19650)the Beneficentia Stiftung,Vaduz(BEN2019/48 and University of Pisa(Rating Ateneo 2019-2020)for the financial support+1 种基金supported by the University of Pisa under the“PRA-Progetti di Ricerca di Ateneo”Institutional Research Grants-Project no.PRA_2020_58“Agenti innovativi e nanosistemi per target molecolari nell’ambito dell’oncologia di precisione”to Marzo Tthe financial support(two-year fellowship for Italy“Marcello e Rosina Soru”-Project Code:23852).
文摘Today colorectal cancer(CRC)is one of the leading causes of cancer death worldwide.This disease is poorly chemo-sensitive toward the existing medical treatments so that new and more effective therapeutic agents are urgently needed and intensely sought.Platinum drugs,oxaliplatin in particular,were reported to produce some significant benefit in CRC treatment,triggering the general interest of medicinal chemists and oncologists for metal-based compounds as candidate anti-CRC drugs.Within this frame,gold compounds and,specifically,the established antiarthritic drug auranofin with its analogs,form a novel group of promising anticancer agents.Owing to its innovative mechanism of action and its favorable pharmacological profile,auranofin together with its derivatives are proposed here as novel experimental agents for CRC treatment,capable of overcoming resistance to platinum drugs.Some encouraging results in this direction have already been obtained.A few recent studies demonstrate that the action of auranofin may be further potentiated through the preparation of suitable pharmaceutical formulations capable of protecting the gold pharmacophore from unselective reactivity or through the design of highly synergic drug combinations.The perspectives of the research in this field are outlined.
